Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Karolinska Development

0,34 SEK

-1,29 %

Mindre end 1K følgere

KDEV

NASDAQ Stockholm

Investment

Financials

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
-1,29 %
-60,41 %
-64,13 %
-65,25 %
-63,90 %
-67,18 %
-81,89 %
-82,42 %
-99,03 %

Karolinska Development is an investment company focused on long-term equity investments in biotechnology and pharmaceutical companies. The company's goal is to develop promising medical innovations stemming from academic research at Karolinska Institutet and other universities in the Nordic region. The company's portfolio includes companies in sectors such as biotechnology and medical technology. Karolinska Development was founded in 2003 and is headquartered in Solna, Sweden.

Læs mere
Markedsværdi
92,91 mio. SEK
Aktieomsætning
866,38 t SEK
Omsætning
1,84 mio.
EBIT %
-497,83 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
13.2
2026

Årsrapport '25

30.4
2026

Delårsrapport Q1'26

12.5
2026

Generalforsamling '26

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelse2.12.2025, 09.23

Notice of Extraordinary General Meeting in Karolinska Development AB (publ)

Karolinska Development
Pressemeddelelse1.12.2025, 10.25

DNB Carnegie Access: Karolinska Development: Aims to strengthen its balance shee

Karolinska Development
Selskabsmeddelelse1.12.2025, 07.00

Karolinska Development AB (publ) announces a rights issue of up to approximately SEK 203 million, subject to subsequent approval by the Extraordinary General Meeting, and proposes change of company name to KDventures AB

Karolinska Development

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse17.11.2025, 08.15

Karolinska Development’s portfolio company Umecrine Cognition publishes data on the benefits of early treatment with golexanolone in Parkinson’s disease

Karolinska Development
Pressemeddelelse17.11.2025, 07.00

DNB Carnegie Access: Karolinska Development: Tough year so far, but news flow set to improve – Q3 review

Karolinska Development
Selskabsmeddelelse14.11.2025, 07.00

Interim Report - January-September 2025

Karolinska Development
Pressemeddelelse4.11.2025, 07.45

Karolinska Development's portfolio company Modus Therapeutics receives approval for second part of phase 2 study in chronic kidney disease with anemia

Karolinska Development
Pressemeddelelse3.11.2025, 10.59

Karolinska Development’s portfolio company BOOST Pharma raises SEK 34 million through directed share issue to Sound Bioventures

Karolinska Development
Pressemeddelelse31.10.2025, 09.55

Karolinska Development’s portfolio company BOOST Pharma presents positive long-term data for its cell-based treatment of Osteogenesis imperfecta

Karolinska Development
Pressemeddelelse28.10.2025, 13.32

DNB Carnegie Access: Karolinska Development: Invests further in BOOST Pharma

Karolinska Development
Pressemeddelelse28.10.2025, 10.06

Karolinska Development invests SEK 7.5 million to support BOOST Pharma’s continued development of BT-101 towards Phase 3

Karolinska Development
Pressemeddelelse24.10.2025, 06.45

Karolinska Development’s portfolio company SVF Vaccines presents positive data from a preclinical study of SVF-001 in chronic hepatitis B and D

Karolinska Development
Pressemeddelelse9.10.2025, 17.24

Karolinska Development's portfolio company PharmNovo receives approval to initiate a phase 2a trial of its drug candidate PN6047 in Spain

Karolinska Development
Pressemeddelelse3.10.2025, 06.30

Karolinska Development’s portfolio company Dilafor receives patent in the US for tafoxiparin in priming of labor

Karolinska Development
Pressemeddelelse16.9.2025, 07.05

Karolinska Development’s portfolio company AnaCardio completes patient recruitment in phase 2a study of its drug candidate AC01

Karolinska Development
Pressemeddelelse4.9.2025, 06.50

Karolinska Development’s portfolio company Umecrine Cognition publishes data showing sustained effect of golexanolone in a Parkinson’s disease model

Karolinska Development
Pressemeddelelse2.9.2025, 16.36

DNB Carnegie Access: Karolinska Development: Highlights from DNB Carnegie’s Micro & Small Cap Day

Karolinska Development
Pressemeddelelse1.9.2025, 07.56

DNB Carnegie Access: Karolinska Development: NAVPS decline – Q2 review

Karolinska Development
Selskabsmeddelelse29.8.2025, 06.00

Interim Report - January-June 2025

Karolinska Development
Pressemeddelelse28.8.2025, 11.50

Karolinska Development's portfolio company Modus Therapeutics raises SEK 28.3 million in oversubscribed unit issue

Karolinska Development
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.